Ftse Mib
34.815,91
0,00%
DAX
18.742,22
-0,08%
S&P 500
5.221,42
-0,02%
NASDAQ
16.388,24
0,29%
Bitcoin
61.502,00
-2,23%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Zentalis Pharmaceuticals Inc (ZNTL) Zentalis Pharmaceuticals Inc (ZNTL) Notizie

Zentalis Pharmaceuticals Inc

ZNTL
11,75
-0,79 (-6,30%)
14 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/5/202413:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:03EDGAR2Form 8-K - Current report
07/5/202413:00GLOBEZentalis Pharmaceuticals Reports First Quarter 2024..
01/5/202423:30GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
02/4/202422:05GLOBEZentalis Pharmaceuticals to Highlight Preclinical Data..
01/4/202423:30GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
02/3/202400:00GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
29/2/202423:20EDGAR2Form S-8 - Securities to be offered to employees in employee..
29/2/202423:14EDGAR2Form S-3ASR - Automatic shelf registration statement of..
28/2/202413:00GLOBEZentalis Pharmaceuticals to Participate in Upcoming Investor..
27/2/202413:08EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:04EDGAR2Form 8-K - Current report
27/2/202413:00GLOBEZentalis Pharmaceuticals Reports Full Year 2023 Financial..
15/2/202422:12EDGAR2Form 8-K - Current report
14/2/202401:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202413:00GLOBEZentalis Pharmaceuticals to Participate in the Oppenheimer..
13/2/202402:25EDGAR2Form 144 - Report of proposed sale of securities
13/2/202402:25EDGAR2Form 144 - Report of proposed sale of securities
13/2/202402:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202403:29EDGAR2Form 144 - Report of proposed sale of securities
03/2/202403:29EDGAR2Form 144 - Report of proposed sale of securities
03/2/202403:28EDGAR2Form 144 - Report of proposed sale of securities
03/2/202403:27EDGAR2Form 144 - Report of proposed sale of securities
03/2/202403:26EDGAR2Form 144 - Report of proposed sale of securities
01/2/202423:00GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
25/1/202413:03EDGAR2Form 8-K - Current report
25/1/202413:00GLOBEZentalis Pharmaceuticals Strengthens Management Team with..
08/1/202413:03EDGAR2Form 8-K - Current report
08/1/202413:00BWImmunome Exclusively Licenses Zentalis ROR1 Antibody-Drug..
04/1/202402:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202402:19EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202422:49GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
21/12/202323:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202323:39GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
13/11/202323:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202323:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202313:00GLOBEZentalis to Participate in Investor Call Focused on Ovarian..
06/11/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:04EDGAR2Form 8-K - Current report
06/11/202313:18GLOBEZentalis Pharmaceuticals Reports Third Quarter 2023..
01/11/202321:52GLOBEZentalis Pharmaceuticals Announces Inducement Grants Under..
07/10/202301:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/10/202301:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/10/202301:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202323:00EDGAR2Form 8-K - Current report
05/10/202302:28EDGAR2Form 144 - Report of proposed sale of securities
Apertura: 12,57 Min: 11,55 Max: 13,24
Chiusura: 12,54

La tua Cronologia

NASDAQ
ZNTL
Zentalis Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network